28/10/2022 - General information
This is a study cohort comprising 200,000 people, which will be used to study and improve the health of the Spanish population. Dr. Jordi Alonso, head of the Health Services Research Group at the IMIM-Hospital del Mar, is a member of the project's executive committee, which has just completed its first year of work. The Hospital del Mar Medical Research Institute is one of the 21 Spanish institutions that, together with the National Statistics Institute (INE), form part of the IMPaCT Cohort project. This initiative is aimed at creating a cohort of 200,000 people over the age of fifteen and using them to study and improve the health of the population. The project has been running for a year, and a meeting was held at the end of September, in Alcalá de Henares, to analyse its progress.
27/10/2022 - General information
On the occasion of the Pharmacist's Day, last October 18, the Barcelona College of Pharmacists awarded the Prize for the best community project in the CARGENCORS Study: Cardiovascular Genetic risk score for Risk Stratification of patients positive for the SARS-CoV-2 (COVID-19) virus, led by researchers and physicians from the Hospital del Mar Medical Research Institute (IMIM), the Institute of Biomedical Research of Girona. Josep Trueta (IDIBGI), the University Institute for Primary Care Research (IDIAP Jordi Gol) and the University of Vic-Central University of Catalonia.
Més informació "The College of Pharmacists of Barcelona awards the CARGENCORS study"
27/10/2022 - Covid-19
A study by the Hospital del Mar Medical Research Institute and Pompeu Fabra University has found that not all HIV patients respond adequately to the SARS-CoV-2 vaccine. The work has been published in the journal Frontiers in Immunology. Up to 20% of people with HIV being treated with antiretroviral drugs do not regain normal levels of immune cells in their blood. These people, with a depressed immune system, are considered to be at risk of SARS-CoV-2 infection and were prioritised in the COVID-19 vaccination strategy, just as other at-risk groups were. However, until now it was not known how they responded to immunisation with RNA-based vaccines, such as those from Pfizer and BioNTech.
26/10/2022 - Press release
People with low levels of this compound who suffer this pathology have almost a 40% greater risk of dying or being admitted to hospital than those with higher levels. This is according to a study carried out jointly by Hospital Germans Trias i Pujol and the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar). The research team analysed blood samples from 905 patients with heart failure, who were monitored for three years. The results of the study have been published in the Journal of the American College of Cardiology.
24/10/2022 - General information
The principal investigator of the Research Group on Cell-type mechanisms in normal and pathological behavior at the Hospital del Mar Medical Research Institute received this award at the IACM congress held in Switzerland. Every two years, the International Association for Cannabinoid Medicines (IACM) awards different categories of prizes to researchers working in the field of cannabinoids. This year, the selection committee of this international association has decided to award the Young Investigator Award for research in the field of cannabinoids to Dr. Arnau Busquets, principal investigator of the Research Group on Cell-type mechanisms in normal and pathological behavior at the Hospital del Mar Medical Research Institute (IMIM).
Més informació "IACM Young Investigator Award for Dr. Arnau Busquets"
24/10/2022 - General information
Two of the grants are awarded by SEOM itself and the third by the Spanish Lung Cancer Group. Two research projects from the Hospital del Mar and the Hospital del Mar Medical Research Institute have received three grants of support during the congress of the Spanish Society of Medical Oncology, held in Madrid from October 18 to 21. The two projects will analyze different aspects related to immunological markers in different subtypes of lung cancer and in patients with different behaviors in response to immunotherapy.
20/10/2022 - General information
Ramon Diez-Feijóo Varela and Sílvia Ramos Campoy have received two personal grants to develop different research projects. Two researchers from the Hospital del Mar and the Hospital del Mar Medical Research Institute have received two grants from the Spanish Society of Hematology and Hemotherapy, within the framework of the LXIV congress of the organization, held in Barcelona from October 6 to 8. These are personal grants for one year, worth 36,000 euros, renewable for a second year.
19/10/2022 - Press release
A multicentre study involving hospitals in Spain and Portugal, led by Hospital del Mar, shows that these patients already receive enough radiation to treat the disease when the breast affected by the tumour is irradiated directly. The study monitored more than 400 women. The results indicate that the five-year survival rate and relapses are practically identical between those who underwent specific treatment targeting the nodes located in the armpits and those who only received breast radiation. The findings of the OPTIMAL study have been published in the journal Radiation Oncology and can now be applied to clinical practice. Thanks to this fact, patients will need less radiotherapy and will suffer fewer treatment-related side effects.
17/10/2022 - Institutional news
It will analyse the role the circadian rhythm alteration of intestinal microbiota plays in the development of Alzheimer's disease. The project is one of the sixty selected in the ninth call for applications for these grants, which reward highly innovative projects in nine areas of scientific knowledge and culture. The project by IMIM-Hospital del Mar researcher Patrick-Simon Welz, 'Losing the rhythm: host-microbiota circadian communication in Alzheimer's disease', is one of the 60 projects selected in the ninth edition of the Leonardo grants, awarded by the BBVA Foundation. These grants support highly innovative proposals in various scientific and cultural fields. This year, 884 applications were submitted and evaluated by 85 independent experts divided into nine panels.
17/10/2022 - Institutional news
The Section Chief of the Gastrointestinal Surgery Department at Hospital del Mar and researcher at the Hospital del Mar Medical Research Institute became a corresponding member of the RAMC, in a ceremony held on 4 October at the institution's headquarters. Dr. Manuel Pera has been a corresponding member of the Royal Academy of Medicine of Catalonia since 4 October. The appointment was made in a ceremony held at the institution's headquarters, in which the Section Chief of the Surgery Department at Hospital del Mar and coordinator of the Gastroesophageal Carcinogenesis research group at the Hospital del Mar Medical Research Institute (IMIM), gave the speech, 'Improving the quality of care in digestive cancer surgery: the experience of the Spanish EURECCA Oesophagogastric Cancer Registry'. The presentation of the new member was led by Dr. Lluís Grande i Posa, full member of the RAMC and Emeritus Chief of Surgery at Hospital del Mar.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact